Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia.,Mini-Reviews in Medicinal Chemistry

当前位置： X-MOL 学术 › Mini-Rev. Med. Chem. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia.
Mini-Reviews in Medicinal Chemistry ( IF 3.8 ) Pub Date : 2020-01-01 , DOI: 10.2174/1389557519666191029121809
Xu Hu ₁ , Yan Wang ₂ , Xiang Gao ₁ , Shengtao Xu ₃ , Linghe Zang ₄ , Yan Xiao ₁ , Zhanlin Li ₁ , Huiming Hua ₁ , Jinyi Xu ₃ , Dahong Li ₁

Affiliation

First stage human clinical trial (CTR20150246) for HAO472, the L-alanine-(14-oridonin) ester trifluoroacetate, was conducted by a Chinese company, Hengrui Medicine Co. Ltd, to develop a new treatment for acute myelogenous leukemia. Two patents, WO2015180549A1 and CN201410047904.X, covered the development of the I-type crystal, stability experiment, conversion rate research, bioavailability experiment, safety assessment, and solubility study. HAO472 hewed out new avenues to explore the therapeutic properties of oridonin derivatives and develop promising treatment of cancer originated from naturally derived drug candidates. Herein, we sought to overview recent progress of the synthetic, physiological, and pharmacological investigations of oridonin and its derivatives, aiming to disclose the therapeutic potentials and broaden the platform for the discovery of new anticancer drugs.

更新日期：2019-11-01

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>